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schappeliPurpose: To construct a model for the prediction of acute esophagitis in lung cancer patients receiving chemora-
diotherapy by combining clinical data, treatment parameters, and genotyping profile.
Patients andMethods: Data were available for 273 lung cancer patients treated with curative chemoradiotherapy.
Clinical data included gender, age, World Health Organization performance score, nicotine use, diabetes, chronic
disease, tumor type, tumor stage, lymph node stage, tumor location, and medical center. Treatment parameters
included chemotherapy, surgery, radiotherapy technique, tumor dose, mean fractionation size, mean andmaximal
esophageal dose, and overall treatment time. A total of 332 genetic polymorphisms were considered in 112 candi-
date genes. The predicting model was achieved by lasso logistic regression for predictor selection, followed by clas-
sic logistic regression for unbiased estimation of the coefficients. Performance of the model was expressed as the
area under the curve of the receiver operating characteristic and as the false-negative rate in the optimal point
on the receiver operating characteristic curve.
Results: A total of 110 patients (40%) developed acute esophagitis Grade $2 (Common Terminology Criteria for
Adverse Events v3.0). The final model contained chemotherapy treatment, lymph node stage, mean esophageal
dose, gender, overall treatment time, radiotherapy technique, rs2302535 (EGFR), rs16930129 (ENG), rs1131877
(TRAF3), and rs2230528 (ITGB2). The area under the curve was 0.87, and the false-negative rate was 16%.
Conclusion: Prediction of acute esophagitis can be improved by combining clinical, treatment, and genetic factors.
A multicomponent prediction model for acute esophagitis with a sensitivity of 84% was constructed with two clin-
ical parameters, four treatment parameters, and four genetic polymorphisms.  2011 Elsevier Inc.
Prediction, Esophagitis, Radiotherapy, Genetic polymorphisms, Lasso logistic regression.INTRODUCTION
Lung cancer has the highest incidence and mortality rate of
all cancers in Western countries, with most patients present-
ing with advanced-stage disease at the time of diagnosis (1).
The standard of care for locally advanced non–small-cell
lung cancer is concurrent chemoradiotherapy. Treatment
success is, however, still constrained by poor local control
and posttherapy toxicity as acute esophagitis (2, 3).
Numerous studies have attempted to define clinical and do-
simetric predictors of radiation-induced esophagitis (4–21).
Factors found to correlate with important acute esophagitis
include concurrent chemoradiotherapy, lymphatic status, andt requests to: Kim De Ruyck, Ph.D., Ghent University,
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537a number of dose–volumetric parameters. Because the
results varied considerably across different institutions, their
clinical usefulness remains restricted. Simultaneously,
significant research efforts have been made to link genetic
polymorphisms in selected genes to radiation-induced toxicity
(22–30). The majority of these radiogenetics studies
considered patients with breast or prostate cancer, whereas
only a few research groups reported on radiation-induced tox-
icity after radiotherapy for lung cancer (28–31).Because of the
limited genetic studies performed for esophagitis and the
inconsistent outcomes for other radiation-induced toxicities,
genetic biomarkers are not yet implementable in the clinic.Conflicts of interest: none.
Acknowledgments—The authors thank all the study participants and
data managers, Dr. Bart Loeys, and Virginie de Gelder.
Received Jan 25, 2011, Accepted for publication March 8, 2011.
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tribution, clinical parameters, and individual genetic variation
on radiation-induced toxicity may not be evaluated separately.
As a result, studies are emerging that correct for dosimetric and
patient-related risk factorswhen trying to link genetic polymor-
phisms with a clinical phenotype after therapy (29, 31–34).
However, a model to predict susceptibility to radiation in
individual patients is still unavailable. Therefore, we aimed at
constructing a predictive algorithm for acute esophagitis by
combining clinical data, treatment parameters, and genotypic




Two hundred eighty-nine lung cancer patients treated with cura-
tive radiotherapy between February 2004 and August 2009 were
enrolled. Of these, 273 were suited to perform the study (Fig. 1).
A total of 213 patients were recruited from the MAASTRO Clinic
and 60 patients from the Ghent University Hospital. Clinical data
and treatment details are presented in Table 1. The majority of
patients were treated with three-dimensional conformal radiother-
apy (3D-CRT) as opposed to intensity-modulated radiotherapy
(IMRT). Themedian tumor dosewas 60 Gy at 1.5–2.69 Gy per frac-
tion (2 patients received 7.5 Gy per fraction). The details of the dif-
ferent radiotherapy treatment regimens can be found in Appendix
E1 (available online). For the MAASTRO Clinic patients, the dosi-
metric parameters were calculated using a commercial radiother-
apy treatment planning system (XiO; Computerized Medical
Systems, St. Louis, MO). The dosimetric parameters for the Ghent
patients were calculated using an in-house-developed planning sys-
tem, with a final dose computation using a commercial radiother-
apy planning system (Pinnacle; Philips Medical Systems, Best,
The Netherlands). In both centers, the esophagus was delineated
using the external esophageal contour from the cricoid cartilage
to the gastroesophageal junction. Esophageal toxicity was scoredFig. Study flowchart.using the Common Terminology Criteria for Adverse Events scale
version 3.0 (35). Acute esophagitis was defined as dysphagia Grade
$2 at any time during or at maximum 3 months after radiotherapy
treatment. Genomic DNA was obtained from fresh blood (Ghent
samples) or frozen buffy coat (MAASTRO samples) using the
Puregene genomic DNA purification kit (Gentra Systems, Minne-
apolis, MN). The study was approved by the ethics committees of
both centers, and all study participants provided written informed
consent. The MAASTRO Clinic cohort study was filed at
clinicaltrials.gov (no. NCT01084785).
Selection of candidate genes and genetic variations
On the basis of a literature search, a total of 112 candidate genes
belonging to the following categories were considered: early
response genes (n = 15), cytokines and growth factors (n = 14), sig-
nal transduction of cytokines and growth factors (n = 53), adhesion
molecules (n = 9), extracellular matrix genes (n = 13), and others
(n = 8). Single nucleotide polymorphisms (SNPs) were selected
after functional tagging based on evolutionary conserved regions
(ECRs) using ECR Browser (36). The 50 flanking region of each
gene (5 kb) was included to thoroughly examine any possible reg-
ulatory regions. Conserved regions with a minimal length of 100 bp
with minimal 80% equality over four species (mouse, rat, rhesus
monkey, and human) were considered. The criteria for picking
SNPs in the ECRs were as follows: minor allele frequencies in pop-
ulations of Caucasian ethnicity >5%, Illumina SNP score >0.60
(proprietary score used to determine the overall success of the
assay), and no linkage (r2 > 0.80) with other SNPs. Less-
stringent criteria were used for cytokines, their receptors, and cell
adhesion molecules (ECRs of 75% equality over three species).
The selection was expanded with a number of SNPs with a proven
biological function from the literature. Finally, 384 SNPs were
retained (Table E1).
Genotyping and quality control
The DNA quality and quantity were checked before genotyping,
and 7 individuals were omitted from genotyping because of low
DNA quantity. Genotyping was performed using the Illumina Gold-
engate technology (DNAVision, Charleroi, Belgium). Upon com-
pletion of genotyping, quality control (QC) processes were run to
guarantee the accuracy of the genotyped dataset. Two individuals
were dropped on the basis of low genotyping efficiency (<90%).
Single nucleotide polymorphisms were eliminated on the basis of
low reliability of cluster separation, low signal intensity, low call
frequency (<75%), absence of a minor allele in the dataset, and
deviation fromHardy-Weinberg equilibrium (p < 0.0001). After ap-
plication of stringent QC, approximately 3% of the samples and
approximately 13% of the SNPs were eliminated. Overall, QC
was completed yielding 273 individuals and 332 SNPs (Table E1).
Statistics
The predicting model was achieved in two steps. First, lasso
logistic regression was applied to the full dataset, for which the
lasso parameter was chosen so as to maximize the area under the
curve (AUC) of the receiver operator characteristic (ROC) curve.
The latter was estimated from 10-fold cross-validation (37). Sec-
ond, the implied set of predictors was passed to classic logistic
regression for unbiased estimation of the coefficients.
Lasso regression shrinks the coefficient estimates toward zero,
with the degree of shrinkage depending on an additional parameter,
lambda (l). In this way, coefficient estimates can be forced to be
exactly zero, thereby effectively eliminating a number of variables.
Table 1. Clinical and treatment parameters for esophageal toxicity
Parameter All (n = 273) Grade 0–1 (n = 163) Grade 2+ (n = 110)
Clinical parameters
Gender (n)
Men 200 (73.3) 136 (83.4) 64 (58.2)
Woman 73 (26.7) 27 (16.6) 46 (41.8)
Age (y)
Median 66.6 68.5 61.5
Range 42.8–87.0 44.0–87.0 42.8–86.0
WHO performance score (n)
0 88 (32.2) 53 (32.5) 35 (31.8)
1 144 (52.7) 84 (51.5) 60 (54.5)
$2 39 (14.3) 25 (15.3) 14 (12.7)
Missing 2 (0.7) 1 (0.6) 1 (0.9)
Nicotine use (n)
Never 7 (2.6) 4 (2.5) 3 (2.7)
Current 93 (34.1) 48 (29.4) 45 (40.9)
Former 165 (60.4) 107 (65.6) 58 (52.7)
Missing 8 (2.9) 4 (2.5) 4 (3.6)
Diabetes (n)
Yes 23 (8.4) 18 (11.0) 5 (4.5)
No 231 (84.6) 141 (86.5) 90 (81.8)
Missing 19 (7.0) 4 (2.5) 15 (13.6)
Chronic disease* (n)
Yes 7 (2.6) 3 (1.8) 4 (3.6)
No 250 (91.6) 154 (94.5) 96 (87.3)
Missing 16 (5.9) 6 (3.7) 10 (9.1)
Tumor type (n)
NSCLC 209 (76.6) 135 (82.8) 74 (67.3)
SCLC 50 (18.3) 17 (10.4) 33 (30.0)
Missing 14 (5.1) 11 (6.7) 3 (2.7)
Tumor stage (n)
I 40 (14.7) 36 (22.1) 4 (3.6)
II 27 (9.9) 19 (11.7) 8 (7.3)
IIIa 88 (32.2) 59 (36.2) 29 (26.4)
IIIb 102 (37.4) 43 (26.4) 59 (53.6)
IV 5 (1.8) 1 (0.6) 4 (3.6)
Missing 11 (4.0) 5 (3.1) 6 (5.5)
Lymph node stage (n)
N0 83 (30.4) 67 (41.1) 16 (14.5)
N1 20 (7.3) 15 (9.2) 5 (4.5)
N2 95 (34.8) 58 (35.6) 37 (33.6)
N3 64 (23.4) 18 (11.0) 46 (41.8)
Missing 11 (4.0) 5 (3.1) 6 (5.5)
Tumor location (n)
Lower lobe 61 (22.3) 34 (20.9) 27 (24.5)
Other 200 (73.3) 123 (75.5) 77 (70.0)
Missing 12 (4.4) 6 (3.7) 6 (5.5)
Medical center (n)
Ghent University Hospital 60 (22.0) 46 (28.2) 14 (12.7)
MAASTRO Clinic 213 (78.0) 117 (71.8) 96 (87.3)
Treatment parameters
Chemotherapy (n)
No 69 (25.3) 55 (33.7) 14 (12.7)
Sequential 120 (44.0) 83 (50.9) 37 (33.6)
Concurrent 84 (30.8) 25 (15.3) 59 (53.6)
Surgery (n)
Yes 35 (12.8) 25 (15.3) 10 (9.1)
No 238 (87.2) 138 (84.7) 100 (90.9)
Radiotherapy technique (n)
3D-CRT 224 (82.1) 124 (76.1) 100 (90.9)
IMRT 49 (17.9) 39 (23.9) 10 (9.1)
Tumor dose (Gy)
Median 60.0 64.0 54.0
Range 40.0–79.2 40.0–79.2 45.0–79.2
(Continued )
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Table 1. Clinical and treatment parameters for esophageal toxicity (Continued )
Parameter All (n = 273) Grade 0–1 (n = 163) Grade 2+ (n = 110)
Mean fractionation size (Gy)
Median 1.8 1.8 1.8
Range 1.5–7.5 1.5–7.5 1.5–2.5
Mean esophageal dose (Gy)
Median 21.7 16.3 26.1
Range 0.4–45.7 0.4–41.9 3.5–45.7
Missing 22 13 9
Maximum esophageal dose (Gy)
Median 56.3 56.0 56.5
Range 1.1–84.2 1.1–81.8 22.8–84.2
Missing 22 14 8
Overall treatment time (d)
Median 31.0 36.0 25.0
Range 17.0–62.0 17.0–62.0 19.0–61.0
Abbreviations:WHO =World Health Organization; NSCLC = non–small-cell lung cancer; 3D-CRT = three-dimensional conformal radio-
therapy; IMRT = intensity-modulated radiotherapy.
Data in parentheses are percentages.
* Gastroesophageal reflux disease, Barrett’s syndrome, previous larynx carcinoma.
540 I. J. Radiation Oncology d Biology d Physics Volume 81, Number 2, 2011By varying l from 0 to 1, and, for each value of l, evaluating a mea-
sure of predictive value (AUC) by cross-validation, the optimal l is
found. This choice of l corresponds to a fitted lasso regression
model for which a limited set of variables provides an acceptable
level of predictive stability, whereas adding more variables does
not increase the predictive value. As a result, a set of predictors is
obtained for the selected l value (i.e., the lasso step acts as a model
selection procedure). A consequence of the lasso technique is that
all coefficient estimates tend to be downwardly biased. Therefore in
a second step, a classic non-lasso logistic regression was performed
to find unbiased estimates of the coefficients of the selected set of
predictors. Again, the predictive value was evaluated through 10-Table 2. Outcome of m
Parameter Occurrence* (%) Two-SNP m
Model predictors, coefficient (95% CI)
(Intercept) 4.29 (6.45
Concurrent chemotherapy 100 1.70 (0.10,
Lymph node stage N3 100 1.05 (0.21,
Mean esophageal dose 100 0.09 (0.05,
Gender female 100 0.97 (0.26,
Overall treatment time 100 0.02 (0.06
RT technique 3D-CRT 78.8 0.99 (0.08
rs2302535CC (EGFR) 59.4 1.67 (0.31,
rs16930129CC (ENG) 56.4 0.97 (0.19,
rs1131877AG (TRAF3) 47.4 —
rs2230528GA (ITGB2) 44.4 —
Model characteristics, % (95% CI)
Probability thresholdy — 30.7 (21.9,
Misclassification ratey — 23.6 (21.5,
False positive ratey — 28.2 (20.8,
False negative ratey — 16.7 (8.8, 2
AUC — 85.2 (83.9,
Abbreviations: SNP = single nucleotide polymorphism; CI = confiden
formal RT; AUC = area under the curve.
Model expression: ln p/(1 p) = b0 + b1  x1 + b2  x2 + b3  x3 + b4
esophagitis, b = coefficient, x = variable/predictor, and eb1 = increase in
crease of the predictor by 1 unit) when the other predictors remain unch
* Over all imputations and partial fits, how often is the predictor inclu
y In the optimal point on the receiver operator characteristic curve.fold cross-validation. The problem of missing values was sur-
mounted by applying multiple imputation (38–40). For each step
described above, 500 full datasets were imputed using predictive
mean matching for continuous variables and polytomous logistic
regression for categoric variables. The analysis was applied to
each of these full datasets, after which the results were averaged
and the variances of the coefficient estimates were corrected for
the variability added by the imputation. Because the AUC reflects
the full spectrum of misclassification, it is only partially suited in
this study, because our interest goes particularly to the part of the
ROC curve where false negatives are unlikely. To this end,
a criterion for a balanced ‘‘optimal point’’ on the ROC curve wasodeling analyses
odel Four-SNP model Non-SNP model
, 2.14) 4.07 (6.39, 1.76) 3.71 (5.78, 1.65)
2.40) 1.85 (1.10, 2.61) 1.74 (1.06, 2.42)
1.88) 1.24 (0.35, 2.13) 1.02 (0.23, 1.81)
0.13) 0.09 (0.05, 0.14) 0.08 (0.04, 0.12)
1.68) 1.04 (0.30, 1.79) 1.02 (0.34, 1.71)
, 0.01) 0.02 (0.06, 0.02) 0.02 (0.05, 0.02)
, 2.06) 1.05 (0.06, 2.16) 1.10 (0.05, 2.15)
3.03) 1.82 (0.42, 3.21) —
1.75) 0.91 (0.11, 1.72) —
1.14 (1.89, 0.38) —
0.75 (1.47, 0.03) —
39.5) 32.3 (23.9, 40.6) 37.0 (29.3, 44.9)
25.6) 21.2 (19.2, 23.3) 23.9 (21.0, 26.8)
35.5) 24.7 (18.9, 30.6) 24.7 (16.6, 32.5)
4.8) 16.0 (9.9, 22.2) 22.8 (16.6, 29.2)
86.5) 86.7 (85.4, 88.0) 84.1 (82.8, 85.4)
ce interval; RT = radiotherapy; 3D-CRT = three-dimensional con-
 x4 + b5 x5 + b6 x6 +. with p = probability to develop acute
odds for predictor 1 (in the case of continuous variables: for an in-
anged.
ded in the best selected model?
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minimizing the distance to the perfect point of the ROC curve
(top left). This resulted in a threshold for the prediction decision
rule, as well as estimates for the false-negative and false-positive
rates. The confidence intervals (CI) of the coefficients are the ordi-
nary logistic regression CIs, corrected for multiple imputation. All
analyses were performed in R by applying the R package glmnet
(41) for lasso regression and the R package MICE (42) for multiple
imputation.
RESULTS
In total, 351 variables were available for model building.
The 19 clinical/treatment parameters are listed in Table 1,
and the 332 genetic polymorphisms are available in Table
E1. After the variable selection procedure including all vari-
ables that occur in more than 50% of the imputed datasets,
the model contained chemotherapy, lymph node stage,
mean esophageal dose (MED), gender, overall treatment
time (OTT), radiation technique, rs2302535, and
rs16930129 (Table 2). Lowering the variable selection
threshold to 40% resulted in the addition of the rs1131877
and rs2230528 SNPs to the model (Table 2). Estimation of
the predictor coefficients showed that, for both approaches,
the most powerful risk predictors were concurrent chemo-
therapy and the rs2302535CC genotype. The AUCs of the
two-SNPs model and the four-SNPs model were 0.85 and
0.87, respectively. The false-negative rate in the optimal
point of the ROC curve was slightly smaller for the model
including four SNPs (16.0% vs. 16.7%). Analogous to the
representation of the clinical/treatment variables in Table
1, the data for the four SNPs included in the models are pre-
sented in Table 3. Predictor coefficients and model charac-









AA 133 (48.7) 87 (53.4) 46 (41.8)
AC 121 (44.3) 71 (43.6) 50 (45.5)
CC 19 (7.0) 5 (3.1) 14 (12.7)
Missing 0 0 0
rs16930129 (ENG)
CC 207 (75.8) 114 (69.9) 93 (84.5)
CT 64 (23.4) 47 (28.8) 17 (15.5)
TT 2 (0.7) 2 (1.2) 0 (0.0)
Missing 0 0 0
rs1131877 (TRAF3)
AA 164 (60.3) 92 (56.4) 72 (66.1)
AG 95 (34.9) 65 (39.9) 30 (27.5)
GG 13 (4.8) 6 (3.7) 7 (6.4)
Missing 1 0 1
rs2230528 (ITGB2)
GG 151 (55.7) 82 (50.6) 69 (63.3)
GA 107 (39.5) 74 (45.7) 33 (30.3)
AA 13 (4.8) 6 (3.7) 7 (6.4)
Missing 2 1 1
Abbreviation as in Table 2.
Data in parentheses are genotype frequencies.information. This non-SNP model had an AUC of 0.84 and
a false-negative rate in the optimal point of the ROC curve
of 22.8% (Table 2). The 95% CIs for the predictor coeffi-
cients are rather broad, whereas those for the measures of
predictive value are relatively small. This indicates that the
predictive accuracy using the given predictors and coeffi-
cients is stable.DISCUSSION
Acute esophagitis is one of the most important side effects
of high-dose radiotherapy for lung cancer, especially when
combined with concurrent chemotherapy (2, 43).
Currently, the prediction of this side effect is based on
dosimetric parameters of radiotherapy only. However,
these parameters lack sensitivity and specificity to estimate
patient-specific treatment outcome correctly. To increase
their predictive value, additional parameters are required.
Different association studies point to the importance of the
individual genotypic profile in therapy toxicity. Therefore,
this study combined clinical data, treatment parameters,
and genetic variation to develop a predictive multicompo-
nent model for acute esophagitis. Single nucleotide poly-
morphisms in multispecies conserved sequences of
candidate genes were considered. Conserved sequences
have remained similar across the millions of years of evolu-
tion and are believed to indicate regions of biological func-
tion (44). By using conservation to prioritize SNPs, the
chances may be increased that SNPs impacting phenotype
will actually be genotyped. Including genetic variation
data to model building may add to the model’s predictive
value but also complicates the analysis owing to the strong
increase in the number of variables. To get around this prob-
lem, lasso logistic regression was applied because this tech-
nique finds models involving the smallest number of
parameters while preserving predictive value. At the same
time, variable inclusion is based on predictive value (as
opposed to statistical significance) and over-/underfitting is
avoided. In the present study, two clinical (lymph node stage
and gender), four treatment (chemotherapy, MED, OTT, and
radiation technique), and four genetic (rs2302535,
rs16930129, rs1131877, and rs2230528) parameters were
found to be highly predictive for the development of Grade
$2 acute esophageal postradiotherapy toxicity.
Concurrent chemotherapy treatment has been accepted as
a risk factor for acute esophagitis. In our study, in patients
treated without or with concurrent chemotherapy, Grade
$2 acute esophagitis incidences were 27.0% and 70.2%,
respectively. This increase in toxicity for concurrent chemo-
therapy has also been found in a high number of other studies
(4, 5, 14, 16, 18–21). In parallel, published data demonstrate
that the best-studied dosimetric parameters with high levels
of association with acute esophagitis are MED, V20, V30,
V40, V45,V50, and V55 (4–6, 8, 9).
The predicting quality of lymph node stage could be ex-
plained by the correlation between the extent of lymph node
involvement and the irradiated volume and dose to the
542 I. J. Radiation Oncology d Biology d Physics Volume 81, Number 2, 2011esophagus, especially in patients with N3 disease (correla-
tion coefficient with MED, 0.42). The median MED was
29.1 Gy for the N3 group, compared with 18.5 Gy for the
N0/1/2 group. The incidence of Grade$2 acute esophagitis
was 71.9% in the N3 arm, compared with 29.2% in the N0/
1/2 arm. These results generally agree with a number of
other studies that found an association of nodal stage N2/
3 with Grade $2 acute esophagitis (5, 13–15). Although
in previous studies gender was only exceptionally
associated with acute esophagitis (4, 20), it was found to
be a predictor in the present study. The incidence of
Grade $2 acute esophagitis was 63.0% for women and
32.0% for men.
Because of the use of different radiotherapy treatment reg-
imens, treatment times varied considerably between
patients, and treatment duration could be included in the
analysis. As expected according to radiobiologic principles,
short treatment times were found to be predictive for
increased acute esophageal toxicity. This is in line with
some (4, 20) but not all studies (10, 13). Compared with
IMRT, 3D-CRT was predictive for acute esophagitis in the
present study. This may be explained by the shorter
treatment times for patients irradiated with 3D-CRT rather
than by the dose to the esophagus (correlation coefficients
of 0.52 and 0.09, respectively). The median treatment
time was 28 days for the 3D-CRT group and 47 days for
the IMRT group, whereas the median MED was,
respectively, 21.2 Gy and 26.1 Gy. The incidence rate in
the 3D-CRT arm was 44.6%, compared with 20.4% in the
IMRT arm. Alternatively, higher doses of radiation to parts
of the esophagus outside of the planning target volumes,
occurring more in 3D-CRT than in IMRT, may also
explain the higher incidence of esophagitis in the 3D-CRT
group.
The rs2302535 SNP is situated in intron 2 of the epidermal
growth factor receptor gene (EGFR). Epidermal growth fac-
tor receptor plays an important role in cellular signaling and
is central to human tumorigenesis. Because in cancer cells
the activation of EGFR leads to a series of intracellular
signals resulting in increased tumor cell growth and resis-
tance to apoptosis, EGFR inhibitors have found their use
in anticancer treatment (45). In this context, EGFR polymor-
phisms are being studied in relation to disease response and
toxicity after EGFR inhibitor therapy (46, 47). The
rs16930129 SNP (Leu69Leu) is located in exon 2 of the
endoglin gene (ENG). Endoglin is a transforming growth
factor (TGF)-b coreceptor mainly expressed in endothelial
cells. It regulates cell proliferation and is important for
endothelial cell survival and vessel repair. Mutations in
endoglin have been linked to the vascular disease
hereditary hemorrhagic telangiectasia, characterized by
dilated capillaries (telangiectasia) that are prone to rupture
(48). Radiation-induced vascular damage strongly resem-
bles the symptoms of hereditary hemorrhagic telangiectasia
patients, and animal studies showed an important role for
endoglin in the development of radiation-induced normal
tissue damage (49, 50). The rs1131877 SNP (Met129Thr)is situated in exon 3 of the tumor necrosis factor receptor-
associated factor 3 gene (TRAF3). The encoded protein is
a member of the TRAF family, which is important in activat-
ing multiple inflammatory and immune-related processes in-
duced by cytokines such as tumor necrosis factor-a and
interleukin-1 (51). The rs2230528 SNP (Gly273Gly) is
part of exon 7 of the integrin b2 gene (ITGB2). Integrin b2
belongs to the integrin b-chain family proteins that may
combine with a-chain family proteins to form b2 integrins.
These b2 integrins are leukocyte cell adhesion molecules
including LFA-1 and Mac-1, with an important role in
cell-surface–mediated signaling and radiation-mediated in-
flammation. It has been found that radiation induces changes
in the expression of various integrins, with important impli-
cations for tumor control and normal tissue toxicity (52).
Generally, of the four genetic variants that were found to
be predictive for acute esophagitis, three are part of signal
transduction genes of cytokines and growth factors, whereas
one is localized in a gene coding for a cell adhesion mole-
cule. Although the encoded proteins are involved in
radiation-induced reactions, studies linking polymorphisms
in these genes to radiation toxicity have not been performed.
Haploview analysis showed that the EGFR rs2302535 SNP
is tightly linked with two nearby polymorphisms and that
the TRAF3 rs1131877 SNP is strongly linked with a high
number of intronic polymorphisms (mean maximum r2 of
0.96 and 0.98, respectively). A high degree of linkage (r2
> 0.8) with other polymorphisms was not found for the
ENG and the ITGB2 SNPs. At present, the functional role
of any of these polymorphisms is unknown.When a classical
association analysis was performed on the dataset of the
present study, none of the 332 considered SNPs were signif-
icantly associated with Grade$2 acute esophagitis after cor-
rection for multiple testing with either Benjamini-Hochberg
or Bonferroni tests. Only by omitting this correction, a num-
ber of polymorphisms, including the four retained in the
prediction model, were significantly associated with esoph-
agitis. The two TGFb1 SNPs (rs1800469/-509 and
rs1800470/Leu10Pro), which were previously shown to be
significantly associated with radiation-induced esophagitis
or pneumonitis (30, 31), were not significantly associated
with acute esophagitis in the present study and were also
not retained in the model.
The final predictive model including 10 parameters esti-
mates the risk of Grade $2 acute esophagitis with 84.0%
sensitivity and 75.3% specificity. By adding genetic data
to the clinical and treatment parameters, the sensitivity of
the model increased from 77% to 84%. In our opinion, fur-
ther progress is possible by genotyping a higher number of
SNPs in a genome-wide approach. To evaluate the clinical
usefulness of the biomarker, its predictive value was deter-
mined. With an incidence rate of 40% for Grade $2 acute
esophagitis as observed in the patient population of the
present study, the positive predictive value of the biomarker
is 69.4%, and the negative predictive value is 87.4%. In
other words, 7 in 10 patients predicted to suffer from acute
esophagitis will actually develop this toxicity and will
Multicomponent prediction model for acute esophagitis d K. DE RUYCK et al. 543benefit from therapy modification. Likewise, 9 in 10
patients will be correctly predicted as low-risk patients
and will be suitable candidates for dose-escalation studies.
In conclusion, the good performance of the model may bethe basis of new prospective trials for treatment optimiza-
tion in lung cancer patients treated with chemoradiation.
Prospective validation in an independent patient cohort
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